Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Delta-Albaplex Tablets (Canada)

This page contains information on Delta-Albaplex Tablets for veterinary use.
The information provided typically includes the following:
  • Delta-Albaplex Tablets Indications
  • Warnings and cautions for Delta-Albaplex Tablets
  • Direction and dosage information for Delta-Albaplex Tablets

Delta-albaplex Tablets

This treatment applies to the following species:
Manufacturer: Pfizer

(tetracycline hydrochloride, novobiocin, and prednisolone - mfr. std.)

DIN 00813680

For Veterinary Use Only

This oral antibiotic-corticosteroid formulation designed for use in dogs and cats, contains prednisolone, which supplies supportive effects in stressful conditions and anti-inflammatory effects, and a combination of two antibiotics, tetracycline hydrochloride and novobiocin, which supplies additive antibacterial effects against certain bacterial pathogens.

Medicinal ingredients

Each tablet contains:

tetracycline hydrochloride

60 mg

sodium novobiocin

60 mg


1.5 mg

Tetracycline Hydrochloride

Tetracycline hydrochloride is an odourless, yellow, fine crystalline powder which is freely soluble in water and gastric juice. It is absorbed readily from the gastro-intestinal tract. Following oral administration to dogs, peak blood concentrations are obtained within two to four hours, high levels are found at 12 hours, and detectable amounts remain in the serum for at least 24 hours. The antibiotic is excreted principally through the kidney. The spectrum of antimicrobial activity of etracycline hydrochloride includes a broad range of gram-positive and gram-negative bacteria such as alpha and beta Streptococci, many strains of Staphylococci, Klebsiella pneumoniae, certain Clostridia, Shigella, Enterbacter aerogenes, and some strains of Salmonella. Tetracycline hydrochloride is also effective against Entamoeba histolytica, rickettsia, and viruses of the lymphogranuloma-psittacosis-trachoma group.


Novobiocin is an antibiotic produced by Streptomyces niveus and was developed in the Research Laboratories of Pharmacia Animal Health. The crystalline antibiotic has a light yellow to white colour, depending upon the state of subdivision. In contrast to most antibiotics produced by actinomycetes, novobiocin, like penicillin, is acidic in nature and is stable to the degree of acidity or alkalinity present in the gastro-intestinal tract. Following oral administration of 10 mg per kg to dogs, peak blood concentrations are obtained within two or three hours, high levels are found at 12 hours, and detectable amounts remain in the serum for at least 24 hours. When an appreciable amount of novobiocin is present in the serum, the drug diffuses into the pleural and ascitic fluids. Novobiocin does not diffuse into the cerebrospinal fluid. The antibiotic is concentrated in the liver and bile and is excreted in the feces and urine. In vitro studies show that novobiocin is active against both gram-positive and gram-negative bacteria, including some strains of Staphylococcus aureus, Streptococcus haemolyticus, Diplococcus pneumoniae, and some strains of Proteus vulgaris. Novobiocin shows no cross-resistance with penicillin against resistant strains of Staphylococcus aureus. However, in vitro studies indicate that Staphylococcus aureus may develop resistance to novobiocin as with other antibiotics.


Prednisolone, a derivative of hydrocortisone, has greater glucocorticoid activity, greater anti-inflammatory activity, less sodium-retaining effect, and less potassium-losing effect than the parent compound. The glucocorticoid activity of prednisolone is approximately three times that of hydrocortisone, and the dose required to produce a given anti-inflammatory effect in dogs is of the order of one-fourth to one-third of the required dose of hydrocortisone (or about one-fifth of the required dose of cortisone).

Prednisolone exerts an inhibitory influence on the cellular, fibrous, and amorphous components of connective tissue and thereby suppresses the basic processes of inflammation. Vascular permeability is decreased, exudation diminished, migration of inflammatory cells markedly impaired, and antibiotics thus permitted to exert their full effect. In infections characterized by undue stress and overwhelming toxicity, prednisolone therapy, in conjunction with properly indicated antibacterial therapy, is effective in combatting stress, reducing mortality, and improving the general attitude and appetite of the animal being treated.

Combined Antibiotic-adrenocortical Therapy

Delta-albaplex (tetracycline Hydrochloride, Novobiocin, And Prednisolone) Has Been Purposefully Formulated To Facilitate The Combined Use Of Tetracycline Hydrochloride, Novobiocin, And Prednisolone. It Provides The Additive Antibacterial Effect Of The Antibiotics Plus The Anti-stress And Anti-inflammatory Effects Of Prednisolone In A Convenient Tablet Form That Retains, By Virtue Of The Antibiotic-cortisosteroid Ratio, The Advantage Of Adaptable Therapeutic Control. The Growing Emphasis That The Role Of Corticosteroids In The Management Of Bacterial Infections Accompanied By Stress, Toxemia, And Inflammation Is An Adjuvant One And That They Should Be Used To Supplement Standard Antibacterial Therapy Prompted Development Of delta-albaplex (tetracycline Hydrochloride, Novobiocin, And Prednisolone). With This Combined Formulation, It Is Possible To Circumvent Some Of The Real Stress And Inflammatory Problems Encountered In Dogs And Cats Ill With Acute Or Chronic Bacterial Infections.

combined Antibiotic Therapy Offers A Wider Range Of Antibacterial Activity Than Therapy With Single Antibiotics. in Vitro Studies With Tetracycline Hydrochloride And Novobiocin Have Indicated That This Antibiotic Combination Is Effective Against Such Organisms As staphylococcus aureus, streptococcus fecalis, And proteus rettgeri. Moreover, in Vitro Studies Have Shown That The Development Of Resistance By staphylococcus aureus To A Combination Of Tetracycline Hydrochloride And Novobiocin Occurs At A Markedly Slower Rate Than To Either Antibiotic Alone. Studies In Mice Infected With staphylococcus aureus Have Indicated That Tetracycline Hydrochloride And Novobiocin Are Compatible in Vivo Against The Strains Tested. Clinical As Well As Toxicity Studies Conducted In Laboratory Animals Show That Tetracycline Hydrochloride Has A Low Order Of Toxicity Comparable To That Of The Other Tetracyclines. As Determined By Tests In Animals, Novobiocin Has A Relatively Low Order Of Toxicity. In Animals With Bacterial Infections Susceptible To Tetracycline Hydrochloride-novobiocin Therapy, delta-albaplex Tetracycline Hydrochloride, Novobiocin, And Prednisolone Combats Stress And Toxemia And Improves The General Condition Of The Animal. In Addition, It Counteracts Inflammatory Changes, Thus Correcting Circulatory Defects And Permitting The Antibiotics To Exert Their Full Effects.


The product is indicated primarily in acute and chronic bacterial infections by or associated with organisms susceptible to tetracycline hydrochloride or to novobiocin, or by organisms more susceptible to the combination than to either antibiotic alone, and in which stress and inflammation are important contributing factors. They are indicated in the following canine and feline infections, when caused by tetracycline hydrochloride-sensitive and novobiocin-sensitive organisms, when accompanied by undue stress, toxemia or inflammation: Acute bronchitis, staphylococcal dermatitis, pneumonia, tonsillitis, and post-operatively for prophylaxis.

The combination is also indicated in mixed bacterial infections occurring in the course of canine and feline viral diseases, such as canine distemper and pneumonitis. Beneficial results achieved in these viral diseases must be attributed to the control of secondary bacterial invaders rather than to any specific antiviral effect. All necessary procedures for the establishment of a bacterial diagnosis should be carried out whenever possible before the institution of therapy. Combined antibiotic-corticosteroid therapy does not obviate the need for indicated surgical procedures.


As with other adrenocortical steroids, the product is contraindicated in animals with tuberculosis, Cushingoid syndrome, and peptic ulcer.

Delta-Albaplex Tablets Caution

In the following conditions the product should be used with caution: diabetes mellitus, osteoporosis, predisposition to thrombophlebitis, hypertension, congestive heart failure, and renal insufficiency.

Use of tetracycline during tooth development (late prenatal and early postnatal periods) may cause discolouration of the teeth.

Side Effects

Because of the wide antibacterial effect of the antibiotic combination on intestinal flora, a change in the character of the stools may be anticipated in certain animals. While rare in animals, if allergic reactions that are not readily controlled by antihistaminic drugs develop during treatment with the product, use of it should be discontinued.

Since the use of any broad-spectrum antibiotic may result in the overgrowth of nonsusceptible organisms, particularly monilia, constant observation of the patient is essential. If new infections appear during therapy, appropriate measures should be taken.

Injudicious use of adrenal hormones in animals with infections can be hazardous. It is therefore essential that the causative organism be known and that effective antibacterial agents be administered concurrently. Alteration of the inflammatory reaction by corticosteroid therapy may be beneficial; however, it may also mask signs of infection and facilitate the spread of micro-organisms. In addition, systemic manifestations, such as fever and signs of toxemia, may be suppressed. A retardant effect on wound healing has not been encountered with prednisolone, but such a possibility should be considered when it is used in conjunction with surgery.

The over-all incidence of troublesome side effects is less with prednisolone than with the therapeutically equivalent doses of hydrocortisone. While the use of this product in the doses herein recommended is not likely to induce the side effects commonly associated with prolonged or intensive adrenocorticoid therapy, overdosage may give rise to the following: hyperglycemia and glycosuria, nitrogen loss, and suppression of endogenous adrenocortical activity. The most commonly observed symptoms of overdosage in the dog are polydipsia and polyuria.

Administration And Dosage

The size of the dog or cat, the severity of the infection, stress, and inflammation, and the effect desired should be considered in determining the dose. The usual dosage for dogs and cats is:


2 to 7 kg

1 or 2 tablets daily

7 to 14 kg

2 to 4 tablets daily

14 to 27 kg

4 to 6 tablets daily

27 kg and over

6 to 8 tablets daily

Cats (mature)

1 Tablet Every 12 Hours

these Total Daily Doses Should Be Divided And Equally Spaced Over A 24-hour Period. If Clinical Response Is Not Prompt, The Dosage Should Be Increased Temporarily, With Subsequent Reduction To The Usual Dosage As Soon As The Desired Clinical Effect Is Obtained. Antibacterial Treatment Should Be Continued For At Least 48 Hours After The Temperature Has Returned To Normal And All Evidence Of Infection Has Disappeared, And For At Least Three (3) Days After delta-albaplex (tetracycline Hydrochloride, Novobiocin, And Prednisolone) And Other Corticosteroid Therapy Has Been Withdrawn.

continuous Medication With delta-albaplex For Longer Than 10 Days Is Not Recommended Unless Supervised By A Veterinarian.


Store at controlled room temperature 15° C to 30° C.


Delta-albaplex Is Available In Bottles Of 200 Tablets.

pharmacia Animal Health, 40 Centennial Road, Orangeville, On L9w 3t3


Registered trademark of Pharmacia & Upjohn Company. Used under licence by Pfizer Canada Inc.: DELTA-ALBAPLEX

Net Contents:



200 tablets



January, 2002

Nac No.

Pfizer Canada Inc.

Order Desk:   800-663-8888
Toll-Free:   877-633-2001
Technical Services Canada:   800-461-0917
Technical Services USA:   800-366-5288
Every effort has been made to ensure the accuracy of the Delta-Albaplex Tablets information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Delta-Albaplex Tablets product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-05-30